AstraZeneca antibody cocktail succeeds in advanced stage study to treat COVID-19
[ad_1] Oct. 11 (Reuters) – AstraZeneca’s (AZN.L) investigational drug COVID-19 helped reduce the risk of serious illness or death in an advanced study, the British drugmaker said on Monday, a boost to its efforts to develop coronavirus drugs beyond vaccines. The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 … Read more